HONOLULU, September 22, 2021 / PRNewswire-PRWeb / – Rare Cannabinoid Company has launched the world’s first pure CBDV oil for sale. The 500 mg CBDV tincture complements the Hawaiian company’s cannabinoid pharmacy: THCV, Delta-8-THC, CBN, CBG, CBC, CBDA, Rare Hawaiian CBD, Extra Strength 3000 mg CBD, and 1: 1 blends.
While CBDV (cannabidivarin) sounds like CBD (cannabidiol), this varin strain is extremely rare and appears to have exciting potential. CBDV is currently being researched for a pharmaceutical anti-epileptic drug and tested on children with autism spectrum disorder (ASD). In preclinical studies, it has been shown to be able to relieve symptoms of ASA, Rett syndrome, and muscular dystrophy. Other studies in mice and humans have found potential anti-inflammatory and anti-nausea properties.
“We are very excited to be the first to introduce a pure CBDV product and we hope our customers can benefit greatly from it,” said the CEO of Rare Cannabinoid Company Jared Dalgamouni.
The pioneering brand was also the first to make a pure THCV (tetrahydrocannabivarin) oil in 2020 and is launching the first high-strength pure terpene oils this week.
The Rare Cannabinoid Company’s pharmacy concept is based on the idea that customers can mix and match various single extracts of cannabinoids and a full spectrum CBD oil to customize their own blends.
Each cannabinoid is believed to offer unique mental and physical health benefits. For example, THCV acts as a stimulant that increases energy and suppresses appetite, while CBN (cannabinol) promotes relaxation and sleep, CBC (cannabichromene) increases the brain’s “happiness” molecule anandamide and can improve mood, and is derived from hemp Delta-8-THC offers similar euphoric effects and health benefits to cannabis-derived THC with a lower risk of anxiety or paranoia.
“No two cannabinoids are the same like no two people are the same,” said Dalgamouni.
“People use hemp and cannabis products for many different reasons, and they affect people differently. Our extracts are designed so that people can customize their own blend or blends to suit their personal needs, ”he said.
CBDV is a non-psychoactive rare cannabinoid that is similar to CBD, but with some key differences.
Like THCV, CBDV is a varin. Varin contain two fewer carbon atoms than their non-Varian counterparts (THC and CBD). These differences mean that they interact with the human endocannabinoid system in different ways and have unique physiological effects.
CBDV naturally occurs in much smaller amounts than CBD and is therefore more difficult to isolate. Rare Cannabinoid Company is the first to introduce a pure CBDV product. Other CBDV products sold online and in stores contain traces of CBDV in a full-spectrum CBD oil or are bulk isolates that would need to be formulated in a laboratory or manufacturing facility.
While cannabinoids target different markets – such as THCV for weight loss, CBN for sleep, and delta-8-THC for recreational use, CBDV appears to appeal to the health community. Like CBG (cannabigerol), it is being studied for many different medical uses.
One of the most interesting areas that CBDV is being studied for is its potential impact on Autism Spectrum Disorder (ASD). ASD is a developmental disorder that affects communication, social interaction, and repetitive movements. There is currently no approved treatment for the core symptoms of ASA, but new research shows that altered endocannabinoid signaling and immune problems may contribute to ASA.
This experiment tested CBDV treatment on a model of ASD in rats. Scientists found that “treatment with cannabidivarin improves autism-like behavior and restores changes in the hippocampal endocannabinoid system and glia.” CBDV improved the rats’ social skills and short-term memory while reducing their repetitive behavior and hyperlocomotion (constant movement as a result of excessive stimulation of the nervous system).
The CDC estimates that one in 59 children will have ASD. There are only two FDA-approved drugs for the symptoms of ASA, and they cause many negative side effects, including weight gain, increased risk of diabetes, and breast tissue growth. Looking for alternatives, there is currently a study with CBDV compared to a placebo in 100 children and adolescents with ASA between the ages of 5 and 18 years. The study aims to measure the effectiveness of CBDV, particularly in terms of irritability.
CBDV underscores the potential of the cannabinoid and is currently being developed into a drug designed to reduce or prevent seizures by GW Pharmaceuticals. The UK company previously developed Epidiolex, a CBD anti-seizure drug, and says that “CBDV represents an additional pipeline opportunity as next-generation epilepsy therapy”.
In this Duchenne muscular dystrophy (DMD) study, CBDV was found to reduce inflammation and restore and improve muscle function in muscular dystrophy. Duchenne muscular dystrophy is the most common form of muscle wasting disease. The study found that in addition to CBDV, CBD and THCV can also prevent muscle degeneration in DMD patients.
CBDV also shows promise for helping neurological behavior problems related to Rett syndrome. In this study, CBDV was found to be beneficial for memory, neurological, and social deficits associated with Rett Syndrome.
Additionally, CBDV shows potential for reducing nausea in this study and reducing inflammation in this study. This experiment tested CBDV against ulcerative colitis in mice and in biopsies from children and found that CBDV reduced intestinal inflammation.
The Rare Cannabinoid Company provides links to medical research and scientific studies on cannabinoids on its website, but clearly states that none of its products are intended to diagnose, treat, cure, or prevent disease. If customers require additional assistance, please refer to the “Expert Cannabinoid Advice” section on the website for a list of independent cannabinoid health advisors. These doctors, nurses and naturopaths have comprehensive medical practices The United States and many offer telemedicine and video conferencing options. They have a great deal of knowledge about cannabinoids and have worked with the products of the Rare Cannabinoid Company.
The Rare Cannabinoid Company is a leader in the manufacture of rare cannabinoid products. It was founded in the first quarter of 2020 and the products are now sold in more than 200 stores across Europe The United States, on prescription in Brazil, and online. Visit the website to see a map of where to buy rare cannabinoids. Stores can also find more information on the wholesale website. The sister brand of the rare cannabinoid company, Hawaiian Choice, was founded in 2017 and is the most popular CBD brand in Hawaii. It specializes in CBD tinctures, CBD balms, and vegan CBD gums, all made with Hawaiian broad spectrum CBD and real Hawaiian fruits, essential oils, or honey.
Media contact
Jennifer Carlile, Rare Cannabinoid Company, +1(808)762-1313, info@rarecannabinoidco.com
Twitter, LinkedIn, Facebook
SOURCE Rare Cannabinoid Company
source https://www.bisayanews.com/2021/09/22/rare-cannabinoid-company-launches-worlds-first-pure-cbdv-oil-cannabidivarin-is-being-researched-for-autism-muscular-dystrophy-rett-syndrome-and-seizures-news/
No comments:
Post a Comment